Key Points
- CEO Martine Rothblatt sold 9,500 shares of United Therapeutics on May 15 at an average price of $568.11, totaling about $5.4 million. After the sale, Rothblatt still owned 40,513 shares, cutting the position by 19%.
- United Therapeutics shares were slightly lower, opening at $566.99 and slipping 0.3% in the session. The stock remains near its 52-week high of $609.35 and has risen well above its 200-day moving average.
- Recent earnings missed Wall Street expectations, with Q1 EPS of $5.82 versus the $7.00 estimate and revenue of $781.5 million versus $797.4 million expected. Despite the miss, analysts remain generally positive, with an average rating of “Moderate Buy” and a consensus price target of $619.42.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $568.11, for a total value of $5,397,045.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company's stock, valued at approximately $23,015,840.43. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
United Therapeutics Stock Down 0.3%
Shares of UTHR stock opened at $566.99 on Tuesday. The stock has a market cap of $24.07 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60. The business has a 50-day simple moving average of $559.71 and a 200-day simple moving average of $508.76. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business's quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the firm earned $6.63 EPS. Sell-side analysts anticipate that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.
Hedge Funds Weigh In On United Therapeutics
A number of large investors have recently bought and sold shares of the business. Talon Private Wealth LLC acquired a new position in United Therapeutics in the 1st quarter worth about $3,038,000. Royal Bank of Canada raised its holdings in United Therapeutics by 3.3% in the 1st quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company's stock worth $35,075,000 after purchasing an additional 1,864 shares during the period. Elmind Capital LP increased its stake in United Therapeutics by 36.4% during the 1st quarter. Elmind Capital LP now owns 15,000 shares of the biotechnology company's stock worth $8,895,000 after buying an additional 4,000 shares in the last quarter. Eversept Partners LP increased its stake in United Therapeutics by 4.6% during the 1st quarter. Eversept Partners LP now owns 264,271 shares of the biotechnology company's stock worth $156,707,000 after buying an additional 11,679 shares in the last quarter. Finally, Excelsior Advisor Network LLC purchased a new stake in United Therapeutics during the 1st quarter worth approximately $581,000. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
UTHR has been the subject of several analyst reports. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a report on Tuesday, March 31st. TD Cowen boosted their price objective on United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a report on Monday, March 30th. UBS Group boosted their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a report on Thursday, March 5th. HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $619.42.
Check Out Our Latest Analysis on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
